Krabesid-LS Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dyspepsia with associated motility disturbances. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as bloating, nausea, and abdominal discomfort. Rabeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, promoting mucosal healing and symptom relief in acid-related disorders. The sustained-release mechanism ensures prolonged therapeutic plasma concentrations, improving patient compliance and symptom control. Krabesid-LS Capsule SR is indicated for patients with combined acid-related and motility disorders, offering a dual mechanism of action that addresses both acid suppression and gastrointestinal motility enhancement. It is recommended to be taken as prescribed by a healthcare professional, with caution advised in patients with known hypersensitivity to either component, and contraindicated in individuals with gastrointestinal obstruction or perforation. Monitoring for potential side effects such as extrapyramidal symptoms or hypersensitivity reactions is advised during therapy.